XM levert geen diensten aan inwoners van de Verenigde Staten.

XM levert geen diensten aan inwoners van de Verenigde Staten.
A
A

AstraZeneca

Nieuws

Reuters - 12 uur geleden

US natgas prices steady as rising output offset higher demand forecasts

US natgas prices steady as rising output offset higher demand forecasts By Scott DiSavino July 26 (Reuters) - U.S. natural gas futures held near a one-week low on Friday as rising output offset forecasts for more demand over the next two weeks than previously expected during what could be record heat in the Lower 48 U.S. states. Also weighing on prices in recent weeks, as traders noted, was still a tremendous oversupply of gas in storage even though injections have been smaller than usual in 10
A
N
Reuters - 20 uur geleden

Astrazeneca Says ODAC Reviewed Imfinzi In Resectable Lung Cancer

BRIEF-Astrazeneca Says ODAC Reviewed Imfinzi In Resectable Lung Cancer July 26 (Reuters) - AstraZeneca PLC AZN.L : ODAC REVIEWED IMFINZI IN RESECTABLE LUNG CANCER FDA ADVISORY COMMITTEE REVIEWED IMFINZI FOR TREATMENT OF RESECTABLE NON-SMALL CELL LUNG CANCER BASED ON AEGEAN PHASE III TRIAL RESULTS Source text for Eikon: ID:nRSZ9254Xa Further company
A
Reuters - 23 uur geleden

British Business - July 26

PRESS DIGEST-British Business - July 26 July 26 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - Anglo American AAL.L took a $1.6 billion writedown at its Woodsmith mine fertiliser project in Britain. - Britain’s accounting watchdog, the Financial Reporting Council, issued financial sanctions totalling 48.2 million pounds ($61.98 million) in the year to the end of
A
A
Reuters - 1 dag geleden

AstraZeneca Says FDA Acknowledged Imfinzi (Durvalumab) Met Primary Endpoint Of Event-Free Survival

BRIEF-AstraZeneca Says FDA Acknowledged Imfinzi (Durvalumab) Met Primary Endpoint Of Event-Free Survival July 25 (Reuters) - AstraZeneca PLC AZN.L : FDA ADVISORY COMMITTEE REVIEWED IMFINZI FOR TREATMENT OF RESECTABLE NON-SMALL CELL LUNG CANCER BASED ON AEGEAN PHASE III TRIAL RESULTS ASTRAZENECA: FDA ACKNOWLEDGED IMFINZI (DURVALUMAB) MET PRIMARY END
A
Reuters - 2 dagen geleden

US natural gas prices fall 4% on bigger storage build

UPDATE 2-US natural gas prices fall 4% on bigger storage build Adds latest prices By Scott DiSavino July 25 (Reuters) - U.S. natural gas futures fell about 4% to a one-week low on Thursday on a bigger-than-expected storage build, rising output and forecasts for less demand next week than previously projected. Despite the larger build, traders noted it was still smaller than usual for this time of year for the 10th time in 11 weeks.
A
N
Reuters - 2 dagen geleden

US natgas prices ease on rising output ahead of storage report

US natgas prices ease on rising output ahead of storage report By Scott DiSavino July 25 (Reuters) - U.S. natural gas futures eased about 1% to a one-week low on Thursday on rising output and forecasts for less demand next week than previously expected ahead of a federal report expected to show last week's storage build was smaller than usual for a 10th time in 11 weeks.
A
N
Reuters - 2 dagen geleden

STOXX 600 drops to 12-week low as earnings fail to impress

LIVE MARKETS-STOXX 600 drops to 12-week low as earnings fail to impress STOXX 600 down 1.2% CAC 40 hits lowest since Jan UMG tumbles after results European semis weak Healthcare shines Wall St futures steady Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com STOXX 600 DROPS TO 12-WEEK LOW AS EARNINGS FAIL TO IMPRESS European equities are in the red on Thursday as the decline in glob
A
R
S
V
E
F
U
G
Reuters - 2 dagen geleden

AstraZeneca PLC reports results for the quarter ended in June - Earnings Summary

AstraZeneca PLC reports results for the quarter ended in June - Earnings Summary AstraZeneca PLC AZN.L reported quarterly adjusted earnings of $1.98​​ per share for the quarter ended in June, lower than the same quarter last year, when the company reported EPS of $2.15. The mean expectation of thirteen analysts for the quarter was for earnings of $1.96 per share.
A
Reuters - 2 dagen geleden

AstraZeneca falls even as quarterly profit in line with market view

BUZZ-AstraZeneca falls even as quarterly profit in line with market view ** Shares of AstraZeneca AZN.L fall 1.4% to 12,040 p ** Co posts qtrly core earnings at $1.98 per share, in line with analysts' forecast ** Raises its sales and profit forecast for 2024 and tops analysts' expectations for second-quarter revenue, buoyed by demand for its therap
A
Reuters - 2 dagen geleden

AstraZeneca Expects About 50% Rise In Tangible Capex In 2024 - Presentation

BRIEF-AstraZeneca Expects About 50% Rise In Tangible Capex In 2024 - Presentation July 25 (Reuters) - AstraZeneca PLC AZN.L : ASTRAZENECA: ANTICIPATE ABOUT 50% INCREASE IN TANGIBLE CAPEX IN 2024 - PRESENTATION ASTRAZENECA: ON TRACK TO DELIVER MID-30S% CORE OPERATING MARGIN BY 2026 - PRESENTATION ASTRAZENECA: BEYOND 2026, WILL TARGET AT LEAST MID-30
A
Reuters - 2 dagen geleden

Ascential Plc, Oxford Instruments, Reckitt Benckiser

EUROPE RESEARCH ROUNDUP-Ascential Plc, Oxford Instruments, Reckitt Benckiser July 25 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Ascential Plc, Oxford Instruments and Reckitt Benckiser, on Thursday. HIGHLIGHTS * Ascential Plc ASCL.L : HSBC raises target price to 568p from 370p * Oxford Instruments OXIG.L : HSBC raises target price to 2850p from 2500p * Reckitt Benckiser RKT.L : HSBC cuts target price to 4800p from 4900p * RS Gr
A
A
A
B
B
C
D
D
E
E
K
K
O
R
S
S
U
A
A
A
B
E
Reuters - 2 dagen geleden

UK Stocks-Factors to watch on July 25

UPDATE 1-UK Stocks-Factors to watch on July 25 Adds new items, updates futures July 25 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Thursday, with futures FFIc1 down 0.6%. * ASTRAZENECA: Anglo-Swedish drugmaker AstraZeneca AZN.L raised its sales and profit forecasts for 2024 and topped analyst expectations for second-quarter revenue, buoyed by demand for its therapies for cancer and rare diseases.
A
B
B
C
I
L
V
A
Reuters - 2 dagen geleden

Global equity slump set to gather momentum in Europe

LIVE MARKETS-Global equity slump set to gather momentum in Europe Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com GLOBAL EQUITY SLUMP SET TO GATHER MOMENTUM IN EUROPE The global equity retreat that has gripped markets looks set to continue in Europe on Thursday, with futures signalling a firmly negative open.
A
K
R
S
E
F
U
G
Reuters - 2 dagen geleden

Sanofi lifts 2024 profit forecast on strength in Dupixent, new products

UPDATE 2-Sanofi lifts 2024 profit forecast on strength in Dupixent, new products Adds share movement and analyst comment in paragraph 3, background on Roche and AstraZeneca in paragraph 4 By Manas Mishra July 25 (Reuters) - Sanofi SASY.PA on Thursday raised its full-year profit outlook after strong demand for blockbuster asthma drug Dupixent and better-than-expected sales of new launches helped its second-quarter results beat estimates.
A
R
S
Reuters - 2 dagen geleden

AstraZeneca raises profit outlook on strong medicines demand

UPDATE 5-AstraZeneca raises profit outlook on strong medicines demand Expects 2024 sales and profit to grow by a mid teens percentage Q2 sales of $12.94 billion beat forecast, core EPS $1.98 in line Shares fell as much as 4% Updates shares in paragraph 4 By Pushkala Aripaka and Maggie Fick July 25 (Reuters) - Anglo-Swedish drugmaker AstraZeneca AZN.L raised its full year sales and profit forecast on Thursday after beating analyst expectations for second-quarter revenue on strong demand for its c
A
G
R
Reuters - 2 dagen geleden

AstraZeneca Sees FY Core EPS Up By A Mid Teens Percentage At CER

BRIEF-AstraZeneca Sees FY Core EPS Up By A Mid Teens Percentage At CER July 25 (Reuters) - AstraZeneca PLC AZN.L : ASTRAZENECA PLC - HALF-YEAR REPORT ASTRAZENECA: FY 2024 GUIDANCE UPGRADE ASTRAZENECA - FY CORE EPS NOW EXPECTED TO INCREASE BY A MID TEENS PERCENTAGE AT CER ASTRAZENECA: FY TOTAL REVENUE AND CORE EPS NOW EXPECTED TO INCREASE BY A MID T
A
Reuters - 2 dagen geleden

AstraZeneca lifts full-year outlook on upbeat demand for therapies

AstraZeneca lifts full-year outlook on upbeat demand for therapies July 25 (Reuters) - Anglo-Swedish drugmaker AstraZeneca AZN.L on Thursday raised its sales and profit forecast for 2024 and topped analyst expectations for second-quarter revenue , buoyed by demand for its therapies for cancer and rare diseases. Reporting by Pushkala Aripaka in Beng
A
Reuters - 2 dagen geleden

Stock rout spreads beyond tech

LIVE MARKETS-Stock rout spreads beyond tech Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com STOCK ROUT SPREADS BEYOND TECH The global equity sell-off looks set to extend into Europe on Thursday although the region may be spared the carnage in parts of Asia, where Japan's Nikkei .N225 tumbled as much as 3% and Hong Kong's Hang Seng .HSI slumped close to 2%.
A
G
H
K
L
N
S
T
U
J
E
F
U
G
Reuters - 2 dagen geleden

Sanofi bumps up full-year forecast after strong Q2 profit

Sanofi bumps up full-year forecast after strong Q2 profit July 25 (Reuters) - Sanofi's SASY.PA second-quarter profit rose 3.2% on strong demand for its blockbuster asthma drug Dupixent and better-than-expected sales of new launches, with the company now expecting a stable full-year profit compared to a prior forecast of a fall. Operating income, excluding one-off items, rose 3.2% to 2.81 billion euros ($3.05 billion), above the 2.08 billion euros expected on average by analysts in a poll on the
A
R
S
Reuters - 2 dagen geleden

Roche lifts 2024 profit guidance on strong drug sales

UPDATE 2-Roche lifts 2024 profit guidance on strong drug sales First-half operating profit growth beats analyst estimates Revenue from eye drug Vabysmo nearly doubles, beats estimates Expects close to 10% adjusted profit growth, up vs previous Shares traded near 1-year high earlier on Thursday Adds details on eye drug in paragraphs 5 and 7, details on CEO's strategy in last two paragraphs By Ludwig Burger FRANKFURT, July 25 (Reuters) - Roche ROG.S on Thursday raised its full-year earnings foreca
A
B
R
R
S

Voorwaarden

Populaire activa

Disclaimer: De entiteiten van de XM Group bieden diensten en toegang tot ons online handelsplatform op basis van uitsluitend-uitvoering, waardoor een persoon de beschikbare content op of via de website kan bekijken en/of gebruiken, zonder dat dit is bedoeld voor wijziging of uitbreiding. Dergelijk(e) toegang en gebruik vallen onder: (i) de algemene voorwaarden; (ii) risicowaarschuwingen; en de (iii) volledige disclaimer. Dergelijke content wordt daarom alleen aangeboden als algemene informatie. Wees u er daarnaast vooral van bewust dat de inhoud op ons online handelsplatform geen verzoek of aanbieding omvat om transacties op de financiële markten uit te voeren. Het beleggen op welke financiële markt dan ook vormt een aanzienlijk risico voor uw vermogen.

Alle materialen die op ons online handelsplatform worden gepubliceerd zijn bedoeld voor educatieve/informatieve doeleinden en omvatten geen – en moeten niet worden beschouwd als het bevatten van – financieel, vermogensbelastings- of handelsadvies en aanbevelingen, of een overzicht van onze handelsprijzen, of een aanbod of aanvraag van een transactie in financiële instrumenten of ongevraagde financiële promoties voor u.

Alle content van derden, alsmede content die is voorbereid door XM, zoals opinies, nieuws, onderzoeken, analyses, prijzen en andere informatie of koppelingen naar externe websites op deze website worden aangeboden op een 'zoals-ze-zijn'-basis, als algemene marktcommentaren, en vormen geen beleggingsadvies. Voor zover dat content wordt beschouwd als beleggingsonderzoek, moet u zich ervan bewust zijn en accepteren dat de content niet bedoeld was en niet is voorbereid in overeenstemming met de wettelijke vereisten die zijn opgesteld om de onafhankelijkheid van beleggingsonderzoek te bevorderen en als zodanig onder de geldende wetgeving en richtlijnen moet worden beschouwd als marketingcommunicatie. Zorg ervoor dat u onze Mededeling over niet-onafhankelijk beleggingsonderzoek en risicowaarschuwing in verband met de voorgaande informatie doorneemt en begrijpt; die kunt u hier lezen.

Risicowaarschuwing: Uw vermogen loopt risico. Hefboomproducten zijn mogelijk niet voor iedereen geschikt. Lees onze informatie over risico's.